Alpha 2.0
Login Register
» Authors » Phillip Parente

Phillip Parente

Explore the profile of Phillip Parente including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 61
Citations 832
Followers 0
Related Specialties
Oncology
General Medicine
Urology
Top 10 Co-Authors
Ian D Davis
Ben Tran
Peter Gibbs
Edmond M Kwan
Francis Parnis
Carmel Pezaro
Angelyn Anton
Javier Torres
Shirley Wong
Arun A Azad
Published In
Asia Pac J Clin Oncol
Intern Med J
Support Care Cancer
J Clin Oncol
BJU Int
Affiliations
Soon will be listed here.
Recent Articles
21.
Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
Azad A, Tran B, Davis I, Parente P, Evans M, Wong S, et al.
Intern Med J . 2021 Mar; 52(8):1339-1346. PMID: 33710759
Background: Docetaxel has emerged as a standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). Uptake of docetaxel for mHSPC in Australia has not previously been reported. Aims: To investigate the real-world...
22.
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease
Schmidt A, Anton A, Shapiro J, Wong S, Azad A, Kwan E, et al.
Asia Pac J Clin Oncol . 2020 Sep; 17(1):36-42. PMID: 32970925
Aim: Optimal treatment for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved, with many patients deriving benefit from the addition of docetaxel to androgen deprivation therapy (D-ADT). This study...
23.
Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic
Underhill C, Parente P, McArthur G, Haydon A, McLachlan S, Wong Z, et al.
Intern Med J . 2020 Sep; 50(10):1282-1285. PMID: 32951279
In response to the COVID-19 pandemic, the Department of Health and Human Services Victoria (DHHS), the Monash Partners Comprehensive Cancer Consortium (MPCCC) and Victorian Comprehensive Cancer Centre (VCCC) pooled their...
24.
Victorian Lung Cancer Service Redesign Project: impacts of a quality improvement collaborative on timeliness and management in lung cancer
Largey G, Briggs P, Davies H, Underhill C, Ross C, Harvey K, et al.
Intern Med J . 2020 Sep; 51(12):2061-2068. PMID: 32896957
Background: Lung cancer management is characterised by a high disease burden, poor survival and substantial variation in management and outcomes. Service redesign provides opportunities for quality improvement (QI) and this...
25.
Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer
Fettke H, Kwan E, Bukczynska P, Ng N, Nguyen-Dumont T, Southey M, et al.
Eur Urol Focus . 2020 Aug; 7(6):1287-1291. PMID: 32739405
Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). However, whether cfDNA...
26.
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, et al.
J Clin Oncol . 2020 Mar; 38(19):2140-2150. PMID: 32182156
Purpose: Lifirafenib is an investigational, reversible inhibitor of B-RAF, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib in...
27.
Outcomes of a randomized controlled trial assessing a smartphone Application to reduce unmet needs among people diagnosed with CancEr (ACE)
Livingston P, Heckel L, Orellana L, Ashley D, Ugalde A, Botti M, et al.
Cancer Med . 2019 Nov; 9(2):507-516. PMID: 31769226
Background: Smartphone technology represents an opportunity to deliver practical solutions for people affected by cancer at a scale that was previously unimaginable, such as information, appointment monitoring, and improved access...
28.
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma
Mason R, Dearden H, Nguyen B, Soon J, Smith J, Randhawa M, et al.
Pigment Cell Melanoma Res . 2019 Oct; 33(2):358-365. PMID: 31587511
The combination of ipilimumab and nivolumab is a highly active systemic therapy for metastatic melanoma but can cause significant toxicity. We explore the safety and efficacy of this treatment in...
29.
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Kwan E, Fettke H, Docanto M, To S, Bukczynska P, Mant A, et al.
Eur Urol Focus . 2019 May; 7(1):63-70. PMID: 31103601
Background: The treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly in recent years. Identifying predictive and/or prognostic biomarkers in the context of this rapidly expanding therapeutic armamentarium...
30.
Patterns of care for stage III non-small cell lung cancer in Australia
Parente P, Chan B, Hughes B, Jasas K, Joshi R, Kao S, et al.
Asia Pac J Clin Oncol . 2019 Mar; 15(3):93-100. PMID: 30868747
Stage III non-small cell lung cancer (NSCLC) makes up a third of all NSCLC cases and is potentially curable. Despite this 5-year survival rates remain between 15% and 20% with...